BiotechTube

Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Castration-Resistant Prostatic Cancer

Conditions

Castration-Resistant Prostatic Cancer, Metastasis

Trial Timeline

Jul 3, 2025 → Feb 24, 2030

NCT ID
NCT06863272

About Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication

Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication is a phase 1/2 stage product being developed by Daiichi Sankyo for Castration-Resistant Prostatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06863272. Target conditions include Castration-Resistant Prostatic Cancer, Metastasis.

What happened to similar drugs?

4 of 20 similar drugs in Castration-Resistant Prostatic Cancer were approved

Approved (4) Terminated (1) Active (15)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅olaparib + enzalutamide + abiraterone acetate + PrednisoneAstraZenecaApproved
✅Darolutamide (Nubeqa, BAY1841788)BayerApproved
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄[Lu-177]-PNT2002 + Abiraterone + EnzalutamideEli LillyPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06863272Phase 1/2Recruiting

Competing Products

20 competing products in Castration-Resistant Prostatic Cancer

See all competitors
ProductCompanyStageHype Score
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
EnzalutamideAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
Crizotinib + EnzalutamideAstellas PharmaPhase 1
29
EnzalutamideAstellas PharmaPhase 2
35
Lu-PSMA + EnzalutamideAstellas PharmaPhase 2
31
EnzalutamideAstellas PharmaApproved
43
enzalutamideAstellas PharmaPre-clinical
26
Enzalutamide + FlutamideAstellas PharmaPhase 2
35
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
26
EnzalutamideAstellas PharmaApproved
43
EnzalutamideAstellas PharmaPhase 2
35
MDV3100Astellas PharmaPre-clinical
26
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
ZEN003694 + EnzalutamideAstellas PharmaPhase 2
42
Enfortumab vedotinAstellas PharmaPhase 2
39
EnzalutamideAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + PlaceboAstellas PharmaPhase 3
40